Immunotherapy has emerged as a valuable treatment option in many advanced malignancies (especially lung cancer). The PD-1 inhibitors (nivolumab and pembrolizumab) and the PD-L1 inhibitors (durvalumab and atezolizumab) have been approved for use in various cancers, alone or in combination with chemotherapy. The protocols for the PD-1/PD-L 1 blockers are listed below. The various indications for these PD-1/PD-L1 blockers, baseline evaluation, monitoring during therapy, and guidelines for the management of immune-related adverse events are described below.
|Number of pages||24|
|Journal||Cancer Research, Statistics, and Treatment|
|Publication status||Published - 01-07-2018|
All Science Journal Classification (ASJC) codes
- Cancer Research
- Drug guides